Multiple myeloma (MM) is a plasma cell (PC) malignancy arising from postgerminal center B cells. In MM patients, the accumulation of abnormal PCs in the bone marrow (BM) alters the homeostatic regulation of both immune and non-immune cells, causes several systemic disorders, including hypercalcemia, renal impairment, anemia, and lytic bone lesions (which are cumulatively known as "CRAB" symptoms). 1 Therefore, MM patients exhibit numerical and functional defects in multiple immune cell subsets, most of which are strongly associated with poor disease outcome.
During the past decade, regulatory T cells (Tregs) Of note, high levels of CD4 + Tregs were also associated with hypercalcemia, the IgA myeloma subtype and reduced numbers of normal PCs. 2 It remains unclear whether myeloma cells stimulate the expansion of Tregs in the course of disease progression or, vice versa, disease progression is accelerated by the Treg-mediated suppression of anticancer immune responses. We believe that these processes are mutually interconnected ( Fig. 1) . Recently, a British study has confirmed that myeloma cells promote the differentiation of Tregs from CD4 + T cells in a cell contact-dependent manner. 3 Such tumor-derived Tregs express higher levels of forkhead box P3 (FOXP3), programmed cell death 1 (PDCD1, best known as PD-1) and tumor necrosis factor receptor superfamily, member 18 (TNFRSF18, also known as glucocorticoid-induced tumor necrosis factor receptor, GITR) than natural Tregs. These findings suggest that myeloma cells harness CD4
+ Tregs to suppress antitumor responses, hence sustaining disease progression (Fig. 1) .
As the molecular mechanisms underpinning the expansion and immunosuppressive functions of CD4 + Tregs are well documented, recent efforts have been dedicated to the identification and functional characterization of CD8 + Tregs in various malignant and inflammatory conditions. CD8 + Tregs exert immunosuppressive functions by several mechanisms, including the cell contact-dependent delivery of inhibitory signals, the secretion of relatively unspecific cytokines and the specific killing of effector immune cells. 4 We were the first to demonstrate that the amount of CD8 + Tregs is significantly increased in MM patients as compared with healthy subjects. Similar to CD4 + Tregs, CD8 + Tregs expressed elevated levels of FOXP3, cytotoxic T lymphocyte antigen-4 (CTLA4) and CD62L, while exhibiting a CD127 −/dim+ phenotype. 5 RT-PCR data confirmed the deregulation of CD8 + Tregs in MM patients, clearly showing that these cells express higher levels of FOXP3 than their normal counterparts. 5 Functional assays revealed that CD8 + Tregs isolated from both MM patients and healthy individuals inhibit the proliferation of CD4 + T cells as well as their ability to secrete IFNγ (but not interleukin-10, IL-10) in a concentration-dependent manner. Of note, CD4 + T cells isolated from MM patients and healthy subjects proliferated similarly in the absence of CD8 + Tregs. 5 These observations suggest that although the proliferative potential of CD4 + T cells from MM patients is intact, these cells are held in check by CD8 + Tregs. Thus, not only CD4 + but also CD48 + Tregs are highly deregulated in MM patients.
The administration of immunomodulatory drugs (IMiDs) is considered as an effective therapeutic regimen for MM patients, as demonstrated by various clinical studies reporting a significant improvement in both disease-free and overall survival. We were therefore interested in assessing whether lenalidomide (one of such IMiDs) affects Tregs in MM patients. To our surprise, the administration of lenalidomide in combination with dexamethasone (a corticosteroid) significantly increased the amount of both CD4 + and CD8 + Tregs in MM patients. 6, 7 Such an increase in immunosuppressive Tregs upon the co-administration of lenalidomide and dexamethasone is paralleled by a decreased in the effector functions of T and NK cells. 8, 9 Thus, an increase in Tregs might compromise the immunotherapeutic effects of lenalidomide in MM patients.
In summary, Tregs accumulate in the course of MM, mediating immunosuppressive effects that favor not only disease progression but also infectious complica- 
